Cargando…

Duration of therapy for locally advanced pancreatic cancer: Does it matter?

INTRODUCTION: Evidence‐based recommendations on duration of multiagent systemic therapy for LAPC are lacking. Herein, we assess the impact of duration of combination systemic therapy on survival of patients with LAPC. METHODS: The National Cancer Database was interrogated to identify patients with u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tuli, Richard, David, John, Lobaugh, Stephanie, Zhang, Zhigang, O'Reilly, Eileen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333837/ https://www.ncbi.nlm.nih.gov/pubmed/32368871 http://dx.doi.org/10.1002/cam4.3081

Ejemplares similares

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
por: O'Reilly, Eileen M., et al.
Publicado: (2020)

Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers
por: David, John M., et al.
Publicado: (2018)

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study
por: Vadhan‐Raj, Saroj, et al.
Publicado: (2020)

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer
por: Peixoto, Renata D’Alpino, et al.
Publicado: (2015)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation
por: He, Chaobin, et al.
Publicado: (2020)

Phase I study of dose‐escalated stereotactic body radiation therapy for locally advanced pancreatic head cancers: Initial clinical results
por: Qing, Shuiwang, et al.
Publicado: (2021)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Impact of aerobic exercise on levels of IL‐4 and IL‐10: results from two randomized intervention trials
por: Conroy, Shannon M., et al.
Publicado: (2016)

High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy
por: Hill, Colin, et al.
Publicado: (2022)

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
por: Hu, Zishuo Ian, et al.
Publicado: (2019)

Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study
por: Singh, Ritu R., et al.
Publicado: (2022)

Reversibility of delirium in Ill‐hospitalized cancer patients: Does underlying etiology matter?
por: Matsuda, Yoshinobu, et al.
Publicado: (2019)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
por: Wolfe, Adam R., et al.
Publicado: (2020)

Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2017)

Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics
por: Chandler, Young, et al.
Publicado: (2021)

Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1)
por: Arcelli, Alessandra, et al.
Publicado: (2020)

The bigger picture of shared decision making: A service design perspective using the care path of locally advanced pancreatic cancer as a case
por: Griffioen, Ingeborg P. M., et al.
Publicado: (2021)

Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I‐II or unresected stage III pancreatic cancer
por: Ma, Sung J., et al.
Publicado: (2019)

Patient and physician opinion of virtual care in the oncology department of an Irish tertiary care centre in the era of Covid-19
por: O’Reilly, Mary, et al.
Publicado: (2021)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta‐analysis
por: Zhong, Xi, et al.
Publicado: (2018)

Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non‐small cell lung cancer
por: Han, James E., et al.
Publicado: (2021)

Reconstructing spleno‐mesenterico‐portal cofluence by bifurcated allogeneic vein in local advanced pancreatic cancer—a feasible method to avoid left‐sided portal hypertension
por: Zhang, Xingmao, et al.
Publicado: (2021)

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
por: Mohindroo, Chirayu, et al.
Publicado: (2021)

Pancreatic Cancer: BRCA Targeted Therapy and Beyond
por: Keane, Fergus, et al.
Publicado: (2023)

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
por: Cowey, C. Lance, et al.
Publicado: (2020)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
por: Yang, Guangjian, et al.
Publicado: (2019)

Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer
por: Feng, Lanyun, et al.
Publicado: (2018)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Predicting Delirium Duration in Elderly Hip-Surgery Patients: Does Early Symptom Profile Matter?
por: Slor, Chantal J., et al.
Publicado: (2013)

Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer
por: Hartvigson, Pehr E., et al.
Publicado: (2019)

Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy
por: Honma, Yoshitaka, et al.
Publicado: (2019)

Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database
por: Vlacich, Gregory, et al.
Publicado: (2017)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer
por: Fischer‐Valuck, Benjamin W., et al.
Publicado: (2019)

Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
por: Yokomizo, Akira, et al.
Publicado: (2021)

Does timing matter in radiotherapy of hepatocellular carcinoma? An experimental study in mice
por: Hassan, Soha A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_trn5ajh5u9286rdfple7bhk2um